GlassScriptPhysician profile
Shea A Edwards
NPI 1063974913
$4,804.00
in general payments reported to CMS, 2019-2025
26 companies · $849 in 2025
The $849 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,177 · 2022: $920 · 2023: $990 · 2024: $868 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,706.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,166.07 | 2021-2025 | |
| Novo Nordisk INC | $803.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $512.85 | 2021-2025 | Trelegy Ellipta |
| Amgen INC. | $405.01 | 2021-2024 | Otezla, Repatha |
| Lilly USA, LLC | $341.04 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.27 | 2021-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $227.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $147.75 | 2022-2023 | Spravato |
| Esperion Therapeutics, INC. | $104.31 | 2021-2024 | Nexletol |
| Exact Sciences Corporation | $88.19 | 2023-2025 | Cologuard Collection Kit |
| Tris Pharma INC | $83.72 | 2023-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.60 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $80.39 | 2024-2025 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $71.75 | 2023-2024 | |
| Organon LLC | $49.43 | 2023 | Nexplanon |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $48.97 | 2025 | Rexulti |
| Renalytix Ai, INC. | $45.73 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $42.81 | 2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $30.08 | 2021 | |
| Dexcom, INC. | $24.46 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $23.40 | 2025 | Veozah |
| Alkermes, INC. | $19.07 | 2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $18.25 | 2025 | Qelbree |
| Pfizer INC. | $17.89 | 2024 | |
| Global Blood Therapeutics, INC. | $15.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shea Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.